镰状细胞病基因治疗后白血病:插入突变、白消安,还是两者皆非?
该文讨论bluebird bio基因治疗试验中受试者发生AML/MDS的事件,分析白消安与插入突变的可能归因,并提出新假说:移植细胞从稳态造血转为再生造血的应激驱动原有前恶性克隆扩增与白血病转化,最终导致AML/MDS。
要点
- 首例AML/MDS未见转基因,归因白消安;最近病例恶性细胞含转基因,提示白消安不太可能贡献。
- SCD人群研究显示AML/MDS相对风险增高但绝对风险低。
- 新假说:基因治疗后造血应激驱动前已存在的前恶性克隆扩增与转化。
核心结论
- 基因治疗后AML/MDS的归因需区分白消安、插入突变或两者皆非,并提出造血应激驱动前恶性克隆扩增的新假说。
研究设计与样本
- 本文为针对bluebird bio基因治疗试验(NCT02140554)中AML/MDS事件的评论/假说性文章,未报告样本量与研究设计细节。
主要发现
- 首例AML/MDS中未检出转基因,故归因于白消安。
- 最近病例的恶性细胞中检出转基因,提示细胞在 白消安治疗后输注,白消安不太可能贡献。
- SCD人群研究显示AML/MDS相对风险增高但绝对风险低。
临床怎么用
- 建议在基因治疗前对SCD个体筛查前白血病祖细胞以验证假说。
- 对严重SCD儿童和成人应考虑合理的替代治愈疗法。
- 正在开展的多中心临床试验纳入非清髓预处理、相关单倍体供者及移植后环磷酰胺。
局限性
- 本文为评论/假说性文章,未报告原始研究样本量、统计阈值或P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recently, encouraging data provided long-awaited hope for gene therapy as a cure for sickle cell disease (SCD). Nevertheless, the transient suspension of the bluebird bio gene therapy trial (clinicaltrials.gov: NCT02140554) after participants developed acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) raised concerns. Potential possibilities for these cases include busulfan, insertional mutagenesis, both, or neither. Busulfan was considered the cause in the first reported case because the transgene was not present in the AML/MDS. However, busulfan is unlikely to have contributed to the most recent case. The transgene was present in the patient's malignant cells, indicating they were infused after busulfan treatment. Several lines of evidence suggest an alternative explanation for events in the bluebird bio trial, including that SCD population studies show an increased relative, but a low absolute, risk of AML/MDS. We propose a new hypothesis: after gene therapy for SCD, the stress of switching from homeostatic to regenerative hematopoiesis by transplanted cells drives clonal expansion and leukemogenic transformation of preexisting premalignant clones, eventually resulting in AML/MDS. Evidence validating our hypothesis will support prescreening individuals with SCD for preleukemic progenitors before gene therapy. While presumed viable, safe strategy has been implemented to resume gene therapy in adults with severe SCD, reasonable alternative curative therapy should be considered for children and adults with severe SCD. Currently, open multicenter clinical trials are incorporating nonmyeloablative conditioning, related haploidentical donors, and posttransplantation cyclophosphamide. Preliminary results from these trials appear promising, and National Institutes of Health-sponsored trials are ongoing in individuals with SCD using this platform.
引用
- Jones RJ, DeBaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood. 2021. PMID: 34115136. doi:10.1182/blood.2021011488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。